This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
by Zacks Equity Research
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks
by Arpita Dutt
The biotech sector's fundamentals remain strong.
Merck's CETP Inhibitor Reduces CV Risk in Phase III Study
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
by Zacks Equity Research
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
Epizyme Progressing Well on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated research report on Epizyme, Inc. (EPZM) on Jun 23, 2017.
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
by Eric Dutram
This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!
Stock Market News for June 22, 2017
by Zacks Equity Research
Energy shares continued to decline on Wednesday, sending the Dow and the S&P 500 lower
Merck's Keytruda on a Roll: Can it Retain the Momentum?
by Zacks Equity Research
As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
by Zacks Equity Research
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More
by Zacks Equity Research
The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
by Zacks Equity Research
Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup
3 Biotech Stocks That More than Doubled Year to Date
by Arpita Dutt
Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
by Arpita Dutt
Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.
Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II
by Zacks Equity Research
Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Company News for June 14, 2017
by Zacks Equity Research
Companies in the News are: LLY,PFE,CAKE,JW.A,CVCO
Merck's Diabetes Drug Meets Primary Endpoint in Key Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.
AbbVie (ABBV) Announced Positive Phase III RA Candidate Data
by Zacks Equity Research
AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).
Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).
Roche Announces Data on Perjeta, Alecensa and Tecentriq
by Zacks Equity Research
Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.